Abstract:The imidazole based 1,2,3 triazole hybrids showed potential p38 MAP kinase anti‐inflammatory inhibitors. Compound 7 c, 7 f and 7 n were found to be most significant comparable to prototype drug Adezmapimod (7 f>7 c>7 n>Adezmapimod). The compound 7 f was the most active compound of the series concerning docking score, ADME studies, and in vitro p38 MAP kinase inhibitory activity. p38 MAP kinases are involved in numerous inflammatory diseases. A series of 14 molecules of 1,2,3 triazole linked 4‐((2‐cyclohexyl‐4,5‐diphenyl‐1H‐imidazol‐1‐yl) methyl)‐1‐phenyl hybrids(7 a–7 n) has been synthesized by click reaction. Spectral data characterized all the synthesized compounds. The final compounds were screened for in vitro p38 MAP kinase inhibitory activity. Three compounds from the series 7 c, 7 f, and 7 n expounded superior activity with IC50 values 234.08±19.65 nM, 222.68±20.69 nM, and 241.70±20.51 nM respectively while two compounds (7 d and 7 e) showed considerable activity compared to prototype drug Adezmapimod (SB203580) (IC50 value 257.13±23.94 nM). The docking study of synthesized molecules revealed that the three compounds (7 f,7 g, and 7 n) showed higher binding affinities than Adezmapimod. The "Desmond v3.6 Program" was utilized to conduct MD simulations. The result revealed that compound 7 f was conformationally stable. The ADME studies were performed using the Swiss ADME algorithm. Studies revealed that all the compound's defiance of Lipinski's rule is within acceptable ranges with few violations. Compound 7 f was orally active and showed good gastrointestinal absorption within the acceptable range. The search for newer compounds with increased activity compared to Adezmapimod resulted in identifying a novel subclass of p38 MAP kinase inhibitors.

Benzothiazole Based Inhibitors of P38α MAP Kinase

The Discovery of (R)-2-(sec-butylamino)-n-(2-methyl-5-(methylcarbamoyl)phenyl) Thiazole-5-carboxamide (BMS-640994)-A Potent and Efficacious P38alpha MAP Kinase Inhibitor.

Design, Synthesis, and Anti-Inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine P38alpha Mitogen-Activated Protein Kinase Inhibitors.

5-amino-pyrazoles as potent and selective p38α inhibitors.

Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38α inhibitors

Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.

Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-n-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical P38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases.

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Novel Strategies for Inhibition of the P38 MAPK Pathway.

Discovery of Pyrrolo[2,1-F][1,2,4]triazine C6-ketones As Potent, Orally Active P38α MAP Kinase Inhibitors.

3d-Qsar And Molecular Docking Studies On Fused Pyrazoles As P38 Alpha Mitogen-Activated Protein Kinase Inhibitors

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Design, synthesis, biological evaluation, and in silico studies of quinoxaline derivatives as potent p38α MAPK inhibitors

Ligand-based 3D pharmacophore design, virtual screening and molecular docking for novel p38 MAPK inhibitors

Synthesis and biological assessment of triazolo-quinazoline carbothioamide derivatives for p38 MAP kinase inhibition: in-silico and in-vitro approaches

Structure-based virtual screening for novel p38 MAPK inhibitors and a biological evaluation

Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives As P38 MAP Kinase Inhibitors by Computational Explorations

Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-Beta Type I Receptor Kinase Domain.

Design, Synthesis, in vitro Anti‐inflammatory Activity and in silico Studies of Imidazole‐Based 1,2,3‐Triazole Hybrids Targeting p38 MAP Kinase

Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain

Machine Learning Assisted Discovery of Novel P38α Inhibitors from Natural Products.